에 대한 최신 뉴스 Humana (NYSE:HUM) 주식

Humana

Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

LOGI

월요일 아침 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 SAP(NYSE:SAP)가 시장 마감 후 분기 이익을 주당 $1.33, 매출을 $92억 9천만 달러로 보고할 것으로 예상하고 있다. SAP 주식은 애프터 마켓에서 0.2% 상승하여 $230.87로 거래되었다.

월요일 주목해야 할 주식: SAP, 뉴코, 퍼블릭 스토리지, 시그나 및 로지텍

Movers

ALNY

COIN

MBLY

MRNA

RIVN

SMMT

STLA

FLSR

이들 11개 대형주들은 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?1. 휴마나(NYSE:HUM)가 별 등급의 2025년 실적 하락과 이것이 2026년 품질 보너스 지급에 어떤 영향을 미칠지에 대해 투자자들에게 업데이트한 후 주가는 24.89% 하락했다. 몇몇 분석가들은 주가 예측을 낮췄다.

코인베이스, 나이키 및 모더나는 지난주 최악의 성과를 보인 11개 대형주 중 일부 (9월 30일-10월 4일)

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Long Ideas

Short Ideas

$BTC

$DOGE

AAPL

AMZN

CSCO

MCHI

NVDA

SAVE

벤징가(Benzinga)는 지난주 많은 투자자들이 선호하는 주식들의 전망을 조사했다. 다음은 저희의 주요 기사 몇 가지이다.
주식들은 금요일에 급등했다. 이는 새로운 데이터에 따르면 9월 비농업 고용이 254,000명 증가하였고, 실업률이 4.1%로 하락하여 4.2%에서 보합세를 유지할 것이라는 전망을 깨뜨린 결과이다.

벤징가 불스 앤 베어스: 엔비디아, 애플, 아마존, 스피릿 항공사 그리고 도지코인 하락 등

Humana Inc

Humanscape

Humacyte Inc

Humble & Fume Inc

Hua Medicine

Humm Group Ltd

Humble Energy Inc

HUMMINGBIRD RES LTD ORD by Hummingbird Resources Ltd

Hummingbird Resources PLC

Humatech Inc

Hedge Funds

General

BLMN

GDDY

Starboard Value's Q3 2024 13F Filing Shows Reduced Stakes In GoDaddy By 32% To 3.13M Shares, Salesforce By 14% To 1.44M Shares, Humana By 62% To 191K Shares, And Bloomin' Brands By 14%

On Monday, Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) said its officials are expected to participate in meetings with investors and analysts over the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41875788/the-cigna-group-affirming-its-capital-priorities" rel="noreferrer noopener">next several weeks</a>.
Additionally, in light of recent and persistent speculation, Cigna confirmed that it is not pursuing a combination with Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>).
&#8220;The Cigna Group remains committed to its established M&amp;A criteria and would only consider acquisitions that are strategically aligned, financially attractive, and have a high probability to close,&#8221; the company added.
During these meetings, Cigna expects to reaffirm its projected full-year 2024 consolidated adjusted EPS outlook of at least $28.40 per share and growth of at least 10% in 2025.
In October, the company reported&nbsp;third-quarter sales of $63.7 billion, up 30% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41656437/cignas-q3-profit-beats-street-on-strong-demand-for-pharmacy-benefit-managements-specialty-drugs-new" rel="noreferrer noopener">consensus of $59.35 billion</a>.
Adjusted income from operations&nbsp;for the third quarter of 2024 increased by 5%, reflecting strong contributions from Evernorth Health Services, particularly within Specialty and Care Services, partially offset by lower net investment income.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41256923/cvs-unitedhealth-request-ftc-chair-recusal-amid-ongoing-pharmacy-benefit-managers-lawsuit" rel="noreferrer noopener">CVS, UnitedHealth Request FTC Chair Recusal Amid Ongoing Pharmacy Benefit Managers Lawsuit</a>
Last month, a Bloomberg report noted that Cigna had reinitiated discussions to merge with Humana. The deal could expand Cigna&#8217;s footprint in Medicare Advantage alongside its commercial insurance prowess while leveraging Humana&#8217;s <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41429974/cigna-and-humana-revive-early-merger-talks-after-year-long-pause-as-medicare-cost-pressure-looms" rel="noreferrer noopener">strong Medicare segment</a>.
Last year, both&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/36007194/whats-going-on-with-healthcare-insurance-giant-cigna-stock-today" rel="noreferrer noopener">companies faced challenges</a> as they navigated federal pressures to reduce Medicare costs, severely impacting Humana&#8217;s market performance and valuation.
Cigna said it continues to deliver shareholder value through focused execution against stated operational and financial targets and via disciplined capital deployment, including dividends and share repurchases.
Year-to-date, the company has repurchased $6 billion of stock, including $1 billion thus far in the fourth quarter.
Cigna expects to continue actively repurchasing its shares in the fourth quarter and 2025.
It will use the majority of proceeds from the sale of its Medicare businesses, which is expected to close in the first quarter of 2025, for share repurchase and has $5.3 billion remaining on its share repurchase authorization.&nbsp;
Price Action: CI stock is up 7.89% at $345, and HUM stock is down 6.29% during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41876225/ars-pharmaceuticals-inks-licensing-pact-for-neffy-allergic-reaction-treatment-analyst-sees-further-stock-upside-despite-200-surge-in-2024" target="_blank" rel="noreferrer noopener">ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024</a></li>
</ul>
Photo via Shutterstock

Large Cap

Guidance

Health Care

Cigna Not Pursuing Humana Merger, Stock Soars

WIIM

Humana shares are trading lower after Cigna confirmed it is not pursuing a combination with the company.

Cigna Confirms It Is Not Pursuing A Combination With Humana

On Wednesday, Donald Trump, the Republican candidate and former president, was elected to the highest office again, marking a return to an administration. His second term is likely to impact U.S. healthcare.
Trump has been unclear about his healthcare policy goals during his campaign. Healthcare <a target="_blank" href="https://www.kff.org/health-care-in-2024-elections-apvotecast-polling/?entry=kff-analysis-of-ap-votecast-abortion-ballot-initiatives" rel="noreferrer noopener">ranked</a> lower than issues like the economy and immigration in voter concerns.
A <a target="_blank" href="https://apnews.com/article/ap-votecast-elections-harris-trump-voters-d5cf4e3611f50ec4349d93ddc7f037cd" rel="noreferrer noopener">poll</a> from the Associated Press found that only 8% of voters viewed healthcare as their top issue, compared to 39% who chose the economy and 20% who picked immigration. Abortion was the leading issue for 11% of voters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Despite his focus on &#8220;Make America Healthy Again,&#8221; millions of Americans may lose health insurance subsidies next year, depending on the political climate after the election and the Republicans&#8217; control of the Senate.
The subsidies, expanded under the 2021 American Rescue Plan, help many, particularly the middle class, afford health insurance through the Affordable Care Act (ACA).
These subsidies are set to expire at the end of 2025, and it remains uncertain whether they will be extended under the new administration.
Trump and other Republicans have opposed continuing the subsidies.
The NBC News <a target="_blank" href="https://www.nbcnews.com/health/health-news/millions-risk-losing-health-insurance-trumps-victory-rcna179146" rel="noreferrer noopener">report</a>, citing some analysts, suggests that the chances of extension could be less than 5% if Republicans win control of the House and the Senate.
Even if Democrats control the House, extending these subsidies seems unlikely. Without an extension, nearly 4 million Americans could lose coverage by 2026 due to unaffordable premiums.
The 2021 changes led to a surge in ACA enrollment, with 15.5 million people benefiting from subsidies across 32 states. The report adds that if the subsidies aren&#8217;t renewed, up to 15.4 million Americans could lose health coverage by 2030.
Another significant issue is Trump&#8217;s stance on Medicare. As president, he supported Medicare Advantage, a private insurer-run program that could eventually replace traditional, government-run Medicare.
The NPR report <a target="_blank" href="https://www.npr.org/sections/shots-health-news/2024/11/07/nx-s1-5183092/trump-election-2024-medicare-advantage" rel="noreferrer noopener">highlights</a> that critics argue that expanding private insurers could increase costs for taxpayers and limit care, with some beneficiaries finding it difficult to switch back to traditional Medicare.
Robert Berenson, a former government official, warned that traditional Medicare could &#8220;wither on the vine.&#8221;
Medicare Advantage grew with the 2003 legislation introducing a drug benefit and expanded private insurers&#8217; role in the program. Although private plans were expected to lower costs, they have been more expensive.
The report also says that in 2023, Medicare Advantage plans cost taxpayers about 6% — or $27 billion — more than traditional Medicare, though some research suggests they offer better care.
The future of healthcare policy in the U.S. will depend on the political dynamics in Congress and Trump&#8217;s second term.
With Republicans pushing for major changes to the ACA and Medicare, experts warn of significant shifts in how Americans access and pay for healthcare in the coming years.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Politics

ALHC

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Laboratory Corporation Of America Holdings

Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

Investors with a lot of money to spend have taken a bearish stance on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HUM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 26 uncommon options trades for Humana.
This isn't normal.
The overall sentiment of these big-money traders is split between 26% bullish and 57%, bearish.
Out of all of the special options we uncovered, 10 are puts, for a total amount of $1,769,622, and 16 are calls, for a total amount of $1,255,541.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $110.0 to $400.0 for Humana during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Humana's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Humana's whale trades within a strike price range from $110.0 to $400.0 in the last 30 days. 
<h3>Humana Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730922355_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.7</td>
<td>$13.4</td>
<td>$16.0</td>
<td>$275.00</td>
<td>$1.2M</td>
<td style="text-align: right;">22</td>
<td style="text-align: right;">841</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$82.9</td>
<td>$75.0</td>
<td>$76.89</td>
<td>$250.00</td>
<td>$384.4K</td>
<td style="text-align: right;">92</td>
<td style="text-align: right;">53</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$18.1</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$270.00</td>
<td>$150.0K</td>
<td style="text-align: right;">396</td>
<td style="text-align: right;">220</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.7</td>
<td>$6.2</td>
<td>$6.6</td>
<td>$400.00</td>
<td>$110.7K</td>
<td style="text-align: right;">758</td>
<td style="text-align: right;">168</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$13.5</td>
<td>$12.5</td>
<td>$12.5</td>
<td>$270.00</td>
<td>$96.2K</td>
<td style="text-align: right;">396</td>
<td style="text-align: right;">311</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Having examined the options trading patterns of Humana, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Humana</h3>
<ul>
<li>Currently trading with a volume of 800,538, the HUM's price is up by 1.69%, now at $259.87. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 78 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Humana, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Unpacking the Latest Options Trading Trends in Humana

B of A Securities analyst Kevin Fischbeck upgrades Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) from Underperform to Neutral and raises the price target from $247 to $308.

Upgrades

Price Target

Analyst Ratings

B of A Securities Upgrades Humana to Neutral, Raises Price Target to $308

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.00</td>
<td>$44.7K</td>
<td>552</td>
<td>2.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$19.00</td>
<td>$57.0K</td>
<td>804</td>
<td>1.7K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$40.6K</td>
<td>292</td>
<td>866</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$210.00</td>
<td>$32.3K</td>
<td>1.6K</td>
<td>719</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$120.00</td>
<td>$142.8K</td>
<td>2.9K</td>
<td>504</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$800.00</td>
<td>$26.5K</td>
<td>379</td>
<td>274</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$232.6K</td>
<td>1.5K</td>
<td>235</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$55.0K</td>
<td>368</td>
<td>155</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$285.00</td>
<td>$34.5K</td>
<td>428</td>
<td>155</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$365.00</td>
<td>$53.5K</td>
<td>215</td>
<td>108</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding ALLK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>), we observe a call option sweep with bullish sentiment. It expires in 45 day(s) on December 20, 2024. Parties traded 819 contract(s) at a $1.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $44.7K, with a price of $55.0 per contract. There were 552 open contracts at this strike prior to today, and today 2319 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option sweep that happens to be bearish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 300 contract(s) at a $19.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $57.0K, with a price of $190.0 per contract. There were 804 open contracts at this strike prior to today, and today 1754 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a call option sweep with bullish sentiment. It expires in 437 day(s) on January 16, 2026. Parties traded 58 contract(s) at a $45.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $40.6K, with a price of $700.0 per contract. There were 292 open contracts at this strike prior to today, and today 866 contract(s) were bought and sold. 
• Regarding ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we observe a call option sweep with bearish sentiment. It expires in 73 day(s) on January 17, 2025. Parties traded 719 contract(s) at a $210.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $32.3K, with a price of $45.0 per contract. There were 1601 open contracts at this strike prior to today, and today 719 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bearish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 340 contract(s) at a $120.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $142.8K, with a price of $420.0 per contract. There were 2969 open contracts at this strike prior to today, and today 504 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bullish sentiment. It expires in 10 day(s) on November 15, 2024. Parties traded 15 contract(s) at a $800.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $1773.0 per contract. There were 379 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 437 day(s) on January 16, 2026. Parties traded 227 contract(s) at a $50.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $232.6K, with a price of $1025.0 per contract. There were 1525 open contracts at this strike prior to today, and today 235 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 163 day(s) on April 17, 2025. Parties traded 77 contract(s) at a $65.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $55.0K, with a price of $715.0 per contract. There were 368 open contracts at this strike prior to today, and today 155 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 10 day(s) on November 15, 2024. This event was a transfer of 75 contract(s) at a $285.00 strike. The total cost received by the writing party (or parties) was $34.5K, with a price of $460.0 per contract. There were 428 open contracts at this strike prior to today, and today 155 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be bullish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 104 contract(s) at a $365.00 strike. This particular call needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $53.5K, with a price of $515.0 per contract. There were 215 open contracts at this strike prior to today, and today 108 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

AMGN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

10 Health Care Stocks Whale Activity In Today's Session

During the last three months, 23 analysts shared their evaluations of Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $297.17, with a high estimate of $400.00 and a low estimate of $247.00. A 19.56% drop is evident in the current average compared to the previous average price target of $369.41. 
<img src="https://www.benzinga.com/files/images/story/2024/1730754056_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Humana by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$268.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$387.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$253.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$260.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$364.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Lance Wilkes</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$308.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$261.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$253.00</td>
<td>$419.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$274.00</td>
<td>$392.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$250.00</td>
<td>$349.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$247.00</td>
<td>$376.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$250.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$396.00</td>
<td>$332.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Humana's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Humana's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Humana analyst ratings.</a>
<h2>Unveiling the Story Behind Humana</h2>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Humana's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Humana's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 11.26%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Humana's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.63%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.8%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Humana's ROA excels beyond industry benchmarks, reaching 0.96%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.74, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Humana

TD Cowen analyst Gary Taylor maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and raises the price target from $261 to $268.

TD Cowen Maintains Hold on Humana, Raises Price Target to $268

Wells Fargo analyst Stephen Baxter maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Overweight and lowers the price target from $387 to $290.

Wells Fargo Maintains Overweight on Humana, Lowers Price Target to $290

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and raises the price target from $250 to $253.

Barclays Maintains Equal-Weight on Humana, Raises Price Target to $253

Wednesday,&nbsp;Humana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) posted third-quarter adjusted EPS of $4.16, down from $7.78 a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.40</a>.
The company reported revenues of $29.30 billion, up 14.7% year-over-year from $25.53 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41619980/humana-reports-third-quarter-2024-financial-results-updates-full-year-adjusted-2024-financial-guid" rel="noreferrer noopener">consensus of $28.67 billion</a>, primarily driven by higher per-member Medicare premiums and Medicare Advantage and state-based contracts membership growth.
Humana&nbsp;ended the third quarter with 16.358 million in total medical membership, compared to 16.963 million a year ago.
Medicare Advantage membership&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/9de77655-133d-44b7-8812-b1e7e15a0c47" rel="noreferrer noopener">reached</a> 5.659 million, up from 5.374 million a year ago.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41429974/cigna-and-humana-revive-early-merger-talks-after-year-long-pause-as-medicare-cost-pressure-looms" rel="noreferrer noopener">Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms</a>
The benefit ratio increased to 89.9% from 86.6% a year ago. The company, in its prepared <a target="_blank" href="https://humana.gcs-web.com/static-files/b42403eb-ea20-46d2-a9e5-729f706c7947" rel="noreferrer noopener">remarks</a>, said the benefit ratio was slightly better than expectations for the third quarter, driven by outperformance in CenterWell Primary Care.
The insurance segment benefit ratio reached 90.6% from 87.6%, in line with the company&#8217;s expectations, supported by slightly higher-than-anticipated member risk scores and in line medical costs in Medicare Advantage business, offset by higher-than-anticipated Medicaid medical costs.
Guidance: Humana raised its 2024 individual Medicare Advantage annual membership growth expectations by 40,000 to 265,000, driven by better-than-expected retention and non-DSNP sales compared to prior guidance of 225,000.
Humana Sees 2024 GAAP EPS of at least $12.89 versus prior guidance of approximately 12.81 compared to the consensus of $13.36.
The insurance giant expects adjusted EPS of at least $16 compared to <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/40070046/insurance-giant-humana-stock-tumbles-after-q2-earnings-beat-issues-sub-par-profit-outlook" rel="noreferrer noopener">prior guidance of around $16.00</a> and a consensus of $16.17.
The company states it is aiming for a Medicare Advantage margin target of at least 3%, though it acknowledges that reaching this goal by 2027 may now be more challenging due to the impact of the <a target="_blank" href="https://www.benzinga.com/government/24/10/41140319/humana-faces-sharp-decline-in-medicare-star-ratings-for-2025-braces-for-2026-revenue-hit" rel="noreferrer noopener">2025 MA Star ratings</a>.
For 2024, Humana reaffirms its insurance segment&#8217;s benefit ratio guidance of approximately 90%, with 91.5%-92% for the fourth quarter.
&#8220;We expect 2025 Adjusted EPS to be at least in line with final 2024 results inclusive of these investments, and provided our 2025 membership change is in line with current expectations,&#8221; Humana&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/b42403eb-ea20-46d2-a9e5-729f706c7947" rel="noreferrer noopener">said</a>.
Price Action: HUM stock is up 3.47% at $266.72 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" target="_blank" rel="noreferrer noopener">Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks</a></li>
</ul>
Photo: T. Schneider via Shutterstock

Humana Lifts 2024 Profit Outlook As Q3 Earnings Beat Street View On Medicare Strength

Humana Exec Says Company Will Approach 2025 With "Similar Posture" As Q3 Strategy

Humana shares are trading higher after the company reported better-than-expected Q3 adjusted EPS and sales.

Humana Sees 2024 GAAP EPS Of At Least $12.89 Versus Prior Guidance Of ~12.81 Vs $13.36 Estimate; Sees Adjusted EPS Of At Least $16 Compared To Prior Guidance Of ~$16.00 Vs $16.17 Estimate

Humana Reports Q3 Adjusted Benefits Expense Ratio Of 89.8% Versus 86.4% A Year Ago

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) reported quarterly earnings of $4.16 per share which beat the analyst consensus estimate of $3.40 by 22.35 percent. This is a 46.53 percent decrease over earnings of $7.78 per share from the same period last year. The company reported quarterly sales of $29.30 billion which beat the analyst consensus estimate of $28.67 billion by 2.20 percent. This is a 14.78 percent increase over sales of $25.53 billion the same period last year.

Earnings Beats

Humana Q3 2024 Adj EPS $4.16 Beats $3.40 Estimate, Sales $29.30B Beat $28.67B Estimate

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has outperformed the market over the past 15 years by 1.4% on an annualized basis producing an average annual return of 13.49%. Currently, Humana has a market capitalization of $31.22 billion. 
Buying $100 In HUM: If an investor had bought $100 of HUM stock 15 years ago, it would be worth $688.29 today based on a price of $259.28 for HUM at the time of writing.
<h3>Humana's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730217619_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have $700 Today

In its upcoming report, Humana (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hum#NYSE">HUM</a>) is predicted by Wall Street analysts to post quarterly earnings of $3.48 per share, reflecting a decline of 55.3% compared to the same period last year. Revenues are forecasted to be $28.66 billion, representing a year-over-year increase of 12.3%.
The current level reflects an upward revision of 1.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company&#39;s earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts&#39; projections for specific key metrics can offer valuable insights.
Bearing this in mind, let&#39;s now explore the average estimates of specific Humana metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, &#39;Revenues- Premiums&#39; should come in at $27.28 billion. The estimate indicates a change of +8.7% from the prior-year quarter.
Analysts forecast &#39;Revenues- Investment income (loss)&#39; to reach $303.08 million. The estimate suggests a change of -1.6% year over year.
The consensus estimate for &#39;Revenues- Services&#39; stands at $1.06 billion. The estimate suggests a change of +4.5% year over year.
The consensus among analysts is that &#39;Revenue- CenterWell&#39; will reach $4.84 billion. The estimate points to a change of +3.8% from the year-ago quarter.
The average prediction of analysts places &#39;Benefits Expense Ratio - Consolidated&#39; at 90.0%. The estimate compares to the year-ago value of 86.6%.
Based on the collective assessment of analysts, &#39;Medical Membership - Group Medicare Advantage&#39; should arrive at 547.91 thousand. The estimate compares to the year-ago value of 510.3 thousand.
Analysts&#39; assessment points toward &#39;Medical Membership - Medicare stand-alone PDP&#39; reaching 2,296.84 thousand. The estimate compares to the year-ago value of 2.89 million.
The collective assessment of analysts points to an estimated &#39;Medical Membership - Individual Medicare Advantage&#39; of 5,613.68 thousand. Compared to the present estimate, the company reported 5.37 million in the same quarter last year.
Analysts expect &#39;Medical Membership - Total Medicare&#39; to come in at 8,458.44 thousand. Compared to the present estimate, the company reported 8.77 million in the same quarter last year.
The combined assessment of analysts suggests that &#39;Medical Membership- State-based contracts and other&#39; will likely reach 1,432.88 thousand. The estimate compares to the year-ago value of 1.26 million.
Analysts predict that the &#39;Medical Membership - Medicare Supplement&#39; will reach 334.07 thousand. Compared to the current estimate, the company reported 299.4 thousand in the same quarter of the previous year.
It is projected by analysts that the &#39;Medical Membership - Military services&#39; will reach 5,956.46 thousand. The estimate compares to the year-ago value of 5.94 million.
<a href="https://www.zacks.com/stock/news/2358419/what-analyst-projections-for-key-metrics-reveal-about-humana-hum-q3-earnings?cid=CS-BENZ-FT-fundamental_analysis|nfm_preview-2358419">To read this article on Zacks.com click here.</a>

What Analyst Projections For Key Metrics Reveal About Humana Q3 Earnings

Cigna Group has decided not to merge with Humana, leading to a rise in Cigna's stock and a drop in Humana's stock.

Cigna's Stock Surges After Dropping Humana Merger Plans

Wall Street Lunch: Nvidia On Top

Dow ends on top while S&P and Nasdaq inch out ahead with CPI data looming

Humana (HUM) announced that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enter...

Humana names Michelle O'Hara as chief human resources officer

Appleseed Fund 2024 Annual  Shareholder Letter

ACSI: A Compelling Thesis Doesn't Make A Good Investment

Medicare to adjust disputed Star Rating measure: Bloomberg News

Medicare to adjust disputed Star Ratings measure: Bloomberg News

Starboard Value adds Autodesk, cuts GoDaddy, others in Q3

Jeffrey Smith's Starboard Value disclosed in an SEC filing its holdings as of September 30, 2024. Starboard's two new buys during the third quarter...

Starboard takes new stakes in Autodesk, Match Group

ABBV

ACSI

ADSK

AGNC

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

ARDX

AVGO

BABA

BBRYF

BOIVF

BOWFF

BSQKZ

BURBY

COST

DLTR

FDLO

FTRE

GOOG

GOOGL

GRVY

LITE

MPWR

MRCY

MSFT

MTCH

NATKY

SAIC

SCHG

SHOP

SPHQ

SPMO

SPYV

SRUUF

URAN

URNM

WLFC

Press Releases

HUM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Humana Inc. and Encourages Investors to Contact the Firm

Humana Reports Third Quarter 2024 Financial Results; Updates Full Year Adjusted 2024 Financial Guidance

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM

Humana and Evolent Expand Partnership to Enhance Oncology Care

Humana Recognized for Commitment to Veteran Employment by Military Times and Military Friendly®

Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Humana Inc. - HUM

Humana Appoints Michelle O'Hara as Chief Human Resources Officer

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

HealthEquity

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

B of A Securities

TD Cowen

Wells Fargo

Barclays

Truist Securities

월요일 아침 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
1. 월스트리트는 SAP(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>)가 시장 마감 후 분기 이익을 주당 $1.33, 매출을 $92억 9천만 달러로 보고할 것으로 예상하고 있다. SAP 주식은 애프터 마켓에서 0.2% 상승하여 $230.87로 거래되었다.
2. 퍼블릭 스토리지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>)는 크리스 삼바(Chris Sambar)를 COO로 임명했다. 퍼블릭 스토리지의 주식은 금요일에 0.1% 상승하여 $345.62로 마감했다.
3. 애널리스트들은 뉴코 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>)가 시장 마감 후 분기 이익을 주당 $1.47, 매출을 $72억 8천만 달러로 보고할 것으로 예상하고 있다. 뉴코의 주식은 금요일에 0.1% 상승하여 $158.24로 마감되었다.
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 보도</a>를 확인해 주세요.
4. 시그나 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)의 주식은 작년에 대화가 끝난 후 회사가 휴매나(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/hum" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for HUM" data-google-interstitial="false">HUM</a>)와의 합병 논의를 재개했다는 보도가 나온 후 시간외 거래에서 주가는 하락했다. 시그나의 주가는 시간외 거래에서 4.7% 하락한 $320.26를 기록했다.
5. 애널리스트들은 로지텍 인터내셔널 S.A.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>)가 시장 마감 후 분기 이익을 주당 $0.99, 매출을 $11억 1천만로 보고할 것으로 예상하고 있다. 로지텍 주식은 금요일에 1.2% 상승하여 $88.63로 마감했다.
다음 내용을 확인해 보세요:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41402086/wall-streets-most-accurate-analysts-give-their-take-on-3-financials-stocks-delivering-hi">월스트리트에서 가장 정확한 애널리스트들이 고배당 수익을 제공하는 3개 금융 주식에 대한 의견을 제시합니다.</a></li>
</ul>
사진 제공: SAP

이들 11개 대형주들은 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 휴마나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)가 별 등급의 2025년 실적 하락과 이것이 <a href="https://www.benzinga.com//node/41140319" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2026년 품질 보너스 지급에 어떤 영향</a>을 미칠지에 대해 투자자들에게 업데이트한 후 주가는 24.89% 하락했다. 몇몇 분석가들은 <a href="https://www.benzinga.com/quote/hum/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측</a>을 낮췄다.
2. 스텔란티스 N.V.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>)의 주가는 크라이슬러 모기업의 미국 판매가 <a href="https://www.benzinga.com//node/41147560" target="_blank" rel="noreferrer noopener">3분기에 20% 급락</a>했다고 발표한 후 17.06% 하락했다. <a href="https://www.benzinga.com//node/41190669" target="_blank" rel="noreferrer noopener">여러</a> 애널리스트들이 <a href="https://www.benzinga.com/quote/stla/analyst-ratings" target="_blank" rel="noreferrer noopener">주식을 하향 조정</a>했다.
3. 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 10.63% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/41171878" target="_blank" rel="noreferrer noopener">MICA 유럽 규정을 충족하지 않는</a> 스테이블코인에 대한 서비스를 제한할 것이라고 발표했다.
4. 모빌아이 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>)의 주식은 10.15% 하락했다.
5. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)는 <a href="https://www.benzinga.com//node/41182921" target="_blank" rel="noreferrer noopener">R1 및 RCV 플랫폼의 공유 부품</a> 공급 부족으로 인해 회사가 연간 생산 지침을 낮춘 후 지난 주 주가는 10% 하락했다.
6. 퍼스트 솔라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLSR#NASDAQ">FLSR</a>)의 주식은 9.63% 하락했다.
7. 콘아그라 브랜즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>)의 주식은 <a href="https://www.benzinga.com//node/41140181" target="_blank" rel="noreferrer noopener">1분기 재무 실적이 예상보다 저조</a>하게 나타났다고 보고한 후 9.12% 하락했다.
8. 플로어 &amp; 데코 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>)의 주식은 8.81% 하락했다.
9. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주가는 8.59% 급락했다. 이 회사는 <a href="https://www.benzinga.com//node/41174110" target="_blank" rel="noreferrer noopener">2차 EGFRm 비소세포폐암(NSCLC) 대상 HARMONi 임상 3상 시험의 등록 완료</a>되었다고 발표했다.
10. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주가는 8.44% 하락했다. 이 회사는 앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)와 진행 중인 특허 침해 소송에서 <a href="https://www.benzinga.com//node/41169029" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">합의에 도달</a>했다.
11. 나이키(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) 주식은 여러 투자 은행들이 <a href="https://www.benzinga.com//node/41147332" target="_blank" rel="noreferrer noopener">1분기 매출 부진에 따라 목표 주가를 하향 조정</a>한 후 8.04% 하락했다.
또한 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A4%91%EA%B5%AD-%EC%A3%BC%EC%8B%9D%EC%9D%B4-%EC%A3%BC%EB%8F%84-%EB%A6%AC-%EC%98%A4%ED%86%A0%EC%99%80-jd%EB%8B%B7%EC%BB%B4%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1/" target="_blank" rel="noopener">미국에 상장된 중국 주식이 또 한 주를 장악 &#8211; 리 오토, JD닷이 지난 주 대형주 상승률 10위 안에 포함되다 (9월 30일~10월 4일): 다른 주식들은 당신의 포트폴리오에 포함되어 있나요?</a></li>
</ul>
사진 출처: rafapress via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

벤징가(Benzinga)는 지난주 <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noopener" data-google-interstitial="false">많은 투자자들이 선호하는 주식</a>들의 전망을 조사했다. 다음은 저희의 주요 기사 몇 가지이다.
주식들은 금요일에 급등했다. 이는 새로운 데이터에 따르면 9월 비농업 고용이 254,000명 증가하였고, 실업률이 4.1%로 하락하여 4.2%에서 보합세를 유지할 것이라는 전망을 깨뜨린 결과이다.
S&amp;P 500은 주간 0.22% 상승했으며, 다우는 0.09%의 소폭 상승으로 마감했다. 나스닥은 금요일에 1% 이상의 손실로 시작했음에도 불구하고 주간 0.1% 상승하여 주목할 만한 반전을 기록했다.
원유 가격은 금요일에 다시 급등하여 거의 9%의 주간 상승률을 기록했다. 이 급등은 중동에서의 긴장이 고조된 후 발생한 것으로, 이란의 미사일 공격이 이스라엘을 겨냥한 사건이다.
중국 기술 주식들은 <a href="https://www.benzinga.com/markets/asia/24/10/41192510/labor-market-surprises-with-strength-energy-stocks-rally-on-israel-iran-tensions-chinese-tech-giants" target="_blank" rel="noopener" data-google-interstitial="false">국내 부양 조치</a>에 대한 기대감이 커지면서 iShares MSCI China ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>)를 통해 강력한 상승세를 보였다.
Benzinga는 투자자들에게 가장 인기 있는 주식에 대한 일일 뉴스를 제공한다. 지난주 가장 긍정적이고 부정적인 기사를 다시 살펴보겠다.
<h3 class="wp-block-heading">강세 주식</h3>
<a href="https://www.benzinga.com/author/ananya-gairola" target="_blank" rel="noopener" data-google-interstitial="false">Ananya Gairola</a>의 <a href="https://www.benzinga.com/news/24/10/41156900/nvidia-ceo-jensen-huang-says-demand-for-next-gen-blackwell-gpu-platform-insane-everyone-wants-to-hav">&#8220;엔비디아의 CEO 젠슨 황은 차세대 블랙웰 GPU 플랫폼에 대한 요구가 엄청나다고 언급. &#8216;누구나 가장 많이 갖고 싶어하며, 모두가 첫 번째가 되고 싶어한다.'&#8221;</a> 기사를 바탕으로 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)의 CEO인 젠슨 황은 새로운 블랙웰(Blackwell) GPU 플랫폼에 대한 압도적인 수요를 강조하며, 이는 현재 전량 생산 중이며 투자자들이 지연에 대해 우려하고 있음에도 불구하고 상당한 매출 성장을 이끌 것으로 기대된다고 밝혔다.
<a href="https://www.benzinga.com/author/aniket-verma" target="_blank" rel="noopener" data-google-interstitial="false">Aniket Verma</a>의 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41136347/is-dogecoins-bullish-momentum-over-after-18-retreat-from-recent-highs-not-yet-say-a">&#8220;최근 최고치에서 18% 하락한 후 도지코인의 강세 모멘텀은 끝났을까? 아직은 아니다고 분석가들이 주장&#8221;</a> 기사는 도지코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)이 18% 하락세를 보였음에도 불구하고, 분석가들인 산티멘트(Santiment)와 알리 마르티네즈(Ali Martinez)가 고래 활동 증가와 추가 상승의 기술적 신호를 인용하며 여전히 강세 잠재력이 남아 있다고 믿고 있음을 강조했다.
<a href="https://www.benzinga.com/author/anusuya-lahiri-0" target="_blank" rel="noopener" data-google-interstitial="false">Anusuya Lahiri</a>의 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41100053/apples-iphone-16-pro-demand-correction-in-sight-analyst-highlights-delivery-trends-">&#8220;애플의 아이폰 16 프로 수요 조정 가시화: 분석가는 글로벌 시장 전반의 배송 추세를 강조&#8221;</a> 기사는 JP모건의 한 분석가가 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)의 아이폰 16 프로 모델에 대한 배송 시간이 안정세를 보이며, 주요 시장인 미국, 중국 및 유럽에서 기본 모델의 리드 타임이 완화되고 있어 수요 조정이 예상된다고 보고했다.
지난주의 추가적인 강세 의견은 다음과 같다:
<a href="https://www.benzinga.com/general/entertainment/24/10/41162458/amazon-ceo-andy-jassy-said-prime-video-will-have-meaningfully-fewer-ads-than-rivals-2-month">아마존의 CEO 앤디 제시는 프라임 비디오가 경쟁사보다 &#8216;의미있게 적은 광고&#8217;를 가질 것이라고 전망. 2개월 후에 스트리밍 거인이 더 많은 광고를 받을 것으로 알려짐</a>
<a href="https://www.benzinga.com/trading-ideas/technicals/24/09/41096549/cisco-set-for-technical-breakout-as-golden-cross-signals-strength-analyst-predicts-stock">골든 크로스가 강세를 나타냄에 따라 시스코는 기술적 돌파구를 마련. 분석가는 주가가 &#8216;조용히&#8217; 상승할 것으로 예측</a>
<a href="https://www.benzinga.com/markets/equities/24/10/41135042/reliable-tesla-number-cruncher-forecasts-biggest-delivery-beat-in-3-years-fund-manager-says-this">신뢰할 수 있는 테슬라 넘버 크런처는 3년 만에 최대 납품 실적 예측: 펀드 매니저는 이것이 주식의 서술을 바꿀 수 있다고 언급</a>
<h3>약세 주식</h3>
<a href="https://www.benzinga.com/author/anthony-noto-0" target="_blank" rel="noopener" data-google-interstitial="false">Anthony Noto</a>의 <a href="https://www.benzinga.com/general/social-media/24/10/41189534/spirit-airlines-bankruptcy-chatter-has-critics-blaming-biden-heres-what-history-shows-about-">&#8220;스피릿 항공 파산 소문, 비난의 대상은 바이든: 항공사 합병에 대한 과거 사례&#8221;</a> 기사는 스피릿 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>)이 어떻게 파산 협상을 진행하고 있는지 살펴보고, 비평가들은 거부된 제트블루(JetBlue) 합병을 비난하고 있다. 과거의 사례를 보면 항공 업계의 합병은 재정적 어려움에 관계없이 일자리 손실로 이어지는 경우가 많다.
<a href="https://www.benzinga.com/author/vandana-singh" target="_blank" rel="noopener" data-google-interstitial="false">Vandana Singh</a>의 <a href="https://www.benzinga.com/government/24/10/41140319/humana-faces-sharp-decline-in-medicare-star-ratings-for-2025-braces-for-2026-revenue-hit">&#8220;휴마나는 2025년 메디케어 별 등급의 급격한 하락에 직면해 2026년 수익 타격을 대비&#8221;</a>의 기사는 휴마나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)가 메디케어 어드밴티지 스타 등급에서 큰 하락을 예상하고 있으며, 25%의 회원만이 4성 이상으로 평가된 계획에 등록되어 있어 2026년에는 상당한 매출 손실로 이어질 수 있다고 보도했다.
<a href="https://www.benzinga.com/author/kaustubh-bagalkote" target="_blank" rel="noopener" data-google-interstitial="false">Kaustubh Bagalkot</a>의 <a href="https://www.benzinga.com/markets/equities/24/09/41086177/amazon-ceo-andy-jassy-faces-employee-revolt-over-full-time-return-to-office-mandate-73-consider-">&#8220;아마존의 CEO 앤디 제시, ​​정규직 복귀 명령에 대해 직원 반란에 직면, 73%가 사직 고려: 설문 조사&#8221;</a>의 기사는 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)의 CEO 앤디 제시가 2025년부터 시행되는 전면 복귀 정책에 대해 내부 반발에 직면해 있으며, 73%의 직원이 퇴사를 고려하고 있어 사기와 유지 문제에 대한 우려가 커지고 있다고 보도했다.
더 많은 부정적 전망은 다음과 같다:
<a href="https://www.benzinga.com/markets/asia/24/10/41141152/cramer-says-hot-money-flowing-from-nvidia-apple-into-china-focus-on-alibaba-if-you-must">크레이머, 엔비디아·애플에서 중국으로 흘러드는 &#8216;핫머니&#8217;, &#8216;해야 한다면&#8217; 알리바바에 집중</a>
<a href="https://www.benzinga.com/markets/asia/24/09/41084907/japans-nikkei-plummets-over-2-000-points-amid-change-of-guard-while-chinese-market-extends-stimulus">일본 닛케이 지수는 총리 교체 속에 2,000포인트 넘게 급락, 중국 시장은 부양책에 힘입어 상승 지속: 아시아 시장 심리를 이끄는 요인</a>
<a href="https://www.benzinga.com/news/24/10/41114769/boeing-dips-in-pre-market-as-struggling-plane-maker-considers-raising-10b-through-stock-sale-amid-st">어려움을 겪고 있는 비행기 제조업체 보잉이 파업 중에 주식 매각을 통해 100억 달러 조달을 고려함에 따라 프리마켓에서 하락</a>
모든 최신 뉴스와 거래 아이디어를 보려면 <a href="https://twitter.com/Benzinga">Benzinga</a>를 트위터에서 팔로우하세요.
Image created using artificial intelligence via Midjourney.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

최고의 트레이더는 공격을 하지 않는다. 그들은 수비를 한다. 그들은 트레이드할 때 반응적이다. 그들은 시장이 그들에게 무엇을 해야 할지 말하도록 놔둔다.
이러한 트레이더들은 시장이 &#8220;기억&#8221;을 가지고 있다는 것을 알고 있다. 이는 중요한 지지선과 저항선이 오랜 기간 동안 유지될 수 있음을 의미한다. 몇 주, 몇 달, 심지어 몇 년이 걸릴 수도 있다.
이 차트에서 보듯이, 이는 휴마나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)의 $225 수준이 그럴 수 있다. 그래서 이를 저희 기술 분석 전문가들 팀이 오늘의 주식으로 선정했다.
주식이 하락세를 보일 때는 수요가 공급을 모두 흡수할 만큼 충분하지 않다는 것이다. 매도자들은 누군가가 주식을 사도록 유도하기 위해 할인된 가격으로 주식을 내놓아야 한다. 이 행동은 주식을 하락세로 몰아넣는다.
하락세는 지지선에 도달했을 때 끝난다. 지지선에서는 수요(매수 주문)가 공급(매도 주문)을 모두 흡수할 만큼 충분하기 때문에 하락세가 멈춘다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3-1024x627.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
휴마나의 차트에서 $225 수준은 2019년 4월에 처음 지지선이 된 후 2020년 3월에도 다시 지지선이 되었다. 이것이 바로 &#8220;시장 기억&#8221;의 사례이다.
지지선은 판매자들이 후회할 경우 오랜 기간 동안 유지될 수 있다. 이들은 지지선에서 주식을 팔았다가 주가가 오르고 가격이 더 오른 후에 그렇게 한 것을 후회한 사람들이다.
실망한 판매자들 중 일부는 자신의 주식을 다시 사겠다고 다짐한다. 그러나 그들은 판매된 가격과 동일한 가격으로 구입할 수 있는 경우에만 그렇게 할 것이다.
결과적으로 주가가 다시 지지선에 도달하면, 이들은 매수 주문을 넣는다. 이러한 매수 주문이 많으면 이전에 지지선이 되었던 가격에서 다시 지지선을 형성하게 된다.
<a href="https://www.benzinga.com/government/24/10/41140319/humana-faces-sharp-decline-in-medicare-star-ratings-for-2025-braces-for-2026-revenue-hit" target="_blank" rel="noopener" data-google-interstitial="false">최근에 몇 가지 실망스러운 뉴스가 있은 후</a>, 휴마나에 매도세가 발생하고 다시 중요한 $225 수준에 가까워지고 있다. 이 가격에 도달하면 시장이 이전에 이 수준이 지지선이었음을 &#8220;기억&#8221;할 가능성이 높다.
이는 주가가 바닥을 찾을 가능성이 높다는 것을 의미한다. 또한, 주가가 이 수준에서 반전되어 상승할 가능성이 높다는 것을 의미한다. 이는 2019년 4월과 2020년 3월과 같은 경우이다.
주가 움직임: 휴마나의 주식은 수요일 11.79% 하락한 $246.49에 마감되었다.
다음 읽기: 
• <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41147552/bitcoin-drops-below-62-000-as-analysts-warn-of-potential-further-decline" target="_blank" rel="noopener" data-google-interstitial="false">분석가들이 추가 하락 가능성을 경고하면서 비트코인이 62,000달러 아래로 하락</a>
Photo: T. Schneider via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Technicals

오늘의 주식: 휴마나가 이전의 지지선을 기억하고 있을까?

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 렌토킬 이니셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>)의 주가가 19.65% 급락했다. 이는 회사가 <a href="https://www.benzinga.com//node/40814655" target="_blank" rel="noreferrer noopener">2024 회계연도 하반기 가이던스</a>를 수정한 후 발생한 일이다.
2. 앨라이 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>)의 주가가 17.31% 급락했다. 이 회사의 CFO가 <a href="https://www.benzinga.com//node/40800069" target="_blank" rel="noreferrer noopener">컨퍼런스에서 차입자들 간의 신용 문제</a>가 심화되고 있음을 언급한 후 여러 애널리스트들이 <a href="https://www.benzinga.com//node/40811970" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>했다.
3. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주가가 11.26% 하락했다. 이 회사가 2027년까지 R&amp;D 비용을 11억 달러 줄이고 <a href="https://www.benzinga.com//node/40834547" target="_blank" rel="noreferrer noopener">2025년 매출 전망을 예상보다 낮게</a> 발표한 후, 많은 애널리스트들이 <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>했다.
4. 휴매나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)의 주가가 9.93% 하락했다. 이는 이번 주의 <a href="https://www.benzinga.com/general/entertainment/24/09/40840076/trump-vs-harris-presidential-debate-viewership-tops-trump-biden-total-but-falls-short-of-re" target="_blank" rel="noreferrer noopener">트럼프-해리스 토론</a>과 관련이 있을 수 있다.
5. 타이슨 푸드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>)의 주가가 7.57% 하락했다.
6. KE 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>)의 주가가 7.14% 하락했다.
7. 어도비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)의 주가가 5.69% 하락했다. 이는 3분기 실적 발표 후 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/ADBE/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측을 하향 조정</a>한 결과이다.
8. 라이언에어 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYAAY#NASDAQ">RYAAY</a>)의 주가가 5.38% 하락했다.
9. JP모건 체이스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)의 주가가 5.05% 하락했다. 이는 COO가 애널리스트의 전망을 완화한 후 발생한 일이다.
10. 데번 에너지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)의 주가가 4.87% 하락했다. JP 모건 애널리스트가 데번 에너지를 비중 확대 등급으로 유지하고 <a href="https://www.benzinga.com/quote/ADBE/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 64달러에서 51달러로 하향 조정</a>했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%B8%84%EC%9D%B4-%EB%B8%8C%EB%A1%9C%EB%93%9C%EC%BB%B4-%EB%B0%8F-arm%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10%EA%B0%9C/" target="_blank" rel="noopener">츄이, 브로드컴 및 ARM은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (9월 8일-9월 14일)</a></li>
</ul>
사진 출처: Lutsenko_Oleksandr on Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ADBE

ALLY

BEKE

RYAAY

모더나, 타이슨 푸드 및 어도비는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 8일-9월 14일)

월요일 시간외 거래에서 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), 휴매나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)와 CVS 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)를 포함한 여러 의료 보험 회사들의 주가가 하락했다. 이는 메디케어 및 메디테이드서비스 센터(CMS)가 <a href="https://www.cms.gov/newsroom/press-releases/cms-finalizes-payment-updates-2025-medicare-advantage-and-medicare-part-d-programs">결제 업데이트를 확정</a>한 후 발생한 일이다.
사건의 전말: CMS는 월요일, 메디케어 어드밴티지(MA) 및 메디케어 파트 D 처방약(파트 D) 프로그램에 대한 2025년도 요율 발표를 확정하고 이 프로그램에 대한 결제 정책을 업데이트하고 결제 정확도를 보장하도록 했다고 발표했다.
이번 요율 발표에 따르면, 2024년부터 2025년까지 평균적으로 정부로부터 MA 계획에 대한 지급이 3.7% 증가할 것으로 예상된다. 또한 2025 년 미 연방정부는 사설 보험 계획에 대해 500 ~ 600 억 달러 사이의 MA 지급을 예상하고 있다.
CMS는 또한 2025년 메디케어 파트 D 약물 혜택 구조를 개선하여 약값을 낮출 예정이라고 밝혔다. 2025년에 메디케어 파트 D를 가입한 사람들의 연간 최대 부담 비용은 2,000 달러로 제한될 것이다.
&#8220;대통령의 하위 처방약에 대한 비용을 낮추게 해주는 인플레이션 감축법(IRA) 덕분에 다음 해에 메디케어 파트 D를 가입한 수백만 명의 사람들은 약값이 더욱 낮아질 것이다. 여러분의 처방약에 대한 금액 지불은 2,000달러를 초과하지 않도록 제한될 것이다. 이로써 여러분은 더 많은 돈을 주머니에 넣을 수 있다&#8221; 라며 미국 보건인구사회부의 자비에르 베서라(Xavier Becerra) 행정부 장관은 말했다.
&#8220;파트 D 약물 혜택 개선은 물론, 이번 결제 업데이트로 인해 이들 프로그램에 의존하는 메디케어 관리 보험 계획에 대한 결제도 개선되었다. 바이든-해리스 행정부는 미국 국민들의 건강 관리 비용을 계속해서 낮추겠다. 이는 대통령이 한 약속을 지키기 위한 것이다.&#8221;
다른 뉴스들: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38030693/galapagos-downgraded-pharma-firm-faces-uphill-battle-with-slow-pipeline-progress">Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst</a>
UNH, HUM, CVS 주가 움직임: 월요일 시간외 거래에서, <a href="http://pro.benzinga.com">Benzinga Pro</a>(벤징가 프로) 따르면, 미국 헬스케어의 주가는 해당 뉴스로 4.5% 하락했다. 휴매나는 9.6% 하락했으며, CVS 주식은 5.92% 빠졌다.
사진: UnitedHealth의 제공

After-Hours Center

Insurance

월요일 장 마감 후 유나이티드헬스, 휴매나, CVS 주식 하락; 왜?

2024년 1분기는 대부분의 자산 클래스에게는 <a href="https://www.benzinga.com/etfs/sector-etfs/24/03/37994542/gold-prices-rise-to-all-time-highs-mark-best-month-in-4-years-mining-stocks-rally-as-traders-ant" target="_blank" rel="noreferrer noopener">대성공이었다</a>. 이러한 강세는 상슨의 지속가능성에 대한 투자자들의 우려를 불러일으켰다. 
이 자산 클래스들의 파티는 언제까지 이어질 것인가? 오버보팅된 시장에 투자하는 데 포함되는 위험은 무엇인가? Benzinga는 이번 랠리가 어떻게 이루어졌는지, 그리고 근거 리스크와 비슷한 기회에 집중해 애널리스트와 경제학자들의 견해를 정리했다.
주식 시장 &#8211; 부진에서 강세로: 주식시장은 새해에 회복세로 출발했는데, 2023년의 급등세가 이어질 것이란 우려가 있었다. 그러나 작년의 힘이 이어졌으며, 이를 통해 회의론이 무너지고 주식시장이 새로운 최고점을 찍었다. 
1분기 동안 S&amp;P 500 지수는 종가 및 일중거래 기록 최고점을 기록했다. 블루칩 주식들도 이러한 성과를 반영하며 다우존스산업평균지수(Dow Jones Industrial Average)는 1분기를 새로운 기록으로 마감했다. 
기술주는 다시 한번 AI 붐을 이끌었으며, 이로 인해 다양한 크기의 회사들은 이익을 창출했다. 그러나 기술주 중심의 나스닥종합지수는 기간 내 상승세 중 일부 이유로 쿼터 말부근 몇몇 이익 실현을 위한 이유로 레코드 피크에 도달하지 못했다. 
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="650" height="450" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/28222154/newplot-7.jpeg" alt="" class="wp-image-269973" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/28222154/newplot-7.jpeg 650w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/28222154/newplot-7-300x208.jpeg 300w" sizes="(max-width: 650px) 100vw, 650px" /></figure>
 출처: Benzinga 
이번 랠리의 더욱 마음이 편한 측면은 2023년과는 다르게 기술주가 아닌 다른 부문에서 더 많은 참여가 이루어졌다는 점이다. 
LPL Financial의 주요 기술 전문가인 아담 턴퀴스트(Adam Turnquist)는 최근 노트에서 S&amp;P 500 지수의 강세 추세가 참여와 순환적 리더십에 의해 지지받고 있다고 말했다. &#8220;종업원들, 금융기업 및 자원은 주로 메가캡스와 AI 열광으로 인해 거의 주목받지 못했던 매력적인 회전을 입증하는 증거를 제시했다&#8221;고 그는 말했다. 
참고 자료:<a target="_blank" href="https://www.benzinga.com/money/how-to-start-investing-in-stocks" rel="noreferrer noopener">주식 초보자 투자 가이드</a>
기간 초반에 AI의 낙관적인 전망은 실리콘엔엔딩 일부 주식의 상승을 견인했는데, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 및 Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)와 같은 기업이 올해 강세를 표명했다. 후반에는 이러한 주식들이 연방준비제도(Fed)의 금리 인하에 대한 경향을 반영하면서 다음과 같은 지지를 받았다.
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td></td>
<td>현재 수준</td>
<td>분기 내 변동</td>
<td>2023년 성과</td>
</tr>
<tr>
<td>나스닥종합지수</td>
<td>16,379.46</td>
<td>+9.11%</td>
<td>+43.42%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,254.35&#x2A;</td>
<td>+10.16%</td>
<td>+24.23%</td>
</tr>
<tr>
<td>다우존스산업평균지수</td>
<td>39,807.37&#x2A;</td>
<td>+5.62%</td>
<td>+13.70%</td>
</tr>
<tr>
<td>러셀 2000지수</td>
<td>2,114.35</td>
<td>+4.31%</td>
<td>+15.09%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">참고: &#x2A; 레코드 종가</figcaption></figure>
이번 분기 S&amp;P 500에서 가장 성과가 좋은 5개 중 3개는 반도체 부문에 속하는 기업들이다. 이는 AI가 이 부문에 주어진 동력을 과시하는 증거로 이어졌다. 이 목록의 선두를 <a target="_blank" href="https://www.benzinga.com/markets/equities/24/03/37440459/palantir-misses-out-super-micro-computer-makes-the-cut-what-investors-should-know-about-s-p-500-" rel="noopener">S&amp;P 500 데뷔자인</a> Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)가 차지했는데, 이 회사는 올해 들어 255% 이상의 수익을 창출했다. 다른 회사들은 다음과 같다: 
<ul>
<li>Nvidia (+83%)</li>
<li>Constellation Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NYSE">CEG</a>): +58%</li>
<li>Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>): +41%</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>): +38%</li>
</ul>
한편, 부정적인 뉴스를 받은 기업들은 S&amp;P 500 종목 중 가장 나쁜 실적을 기록했다. 이 분기 동안에는 우리의 분기에 대한 보고서에서 여기서 29%와 26% 감소했다.
종합선물시장의 불황으로 인해 Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)와 Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)는 부정적인 헤드라인에 타격을 입었는데 소프트웨어 수요의 하락과 공급 측면의 병목 현상, 항공기 안전에 대한 우려 때문이었다..
 차터 커뮤니케이션 (바이커스: <a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), 거래 플랫폼 제공업체 MarketAxess Holdings Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) 및 의료 및 전문 보험 상품 제조업체 Humana, Inc.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)는 이번 분기 성능이 가장 나쁜 몇 가지 기업 중 하나로 선정되었다.
금의 눈부신 성과: 달러의 약세로 인해 금은 22년 만에 최고의 경기 침체를 기록했다. 또한 이에 따라 이는 현재 3월에 22년째로 최고의 경제지표를 나타냈다. 금은 미국 달러화에 역반비례하는 관계를 갖고 있기 때문에 이러한 경제지표에 의해 영향을 받게된다. 
1분기에는 금 선물이 종가를 기록한 2,254.80달러로, 이에 대한 기록적인 눈부시는 최고점으로 마무리 되었다. 
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td></td>
<td>Current Level</td>
<td>QTD Change</td>
<td>2023 Performance</td>
</tr>
<tr>
<td>Gold futures (Price/troy once)</td>
<td>2,254.80&#x2A;</td>
<td>+8.83%</td>
<td>+13.45%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">참고: &#x2A; 레코드 종가</figcaption></figure>
비트코인의 강세: 단순히 증권거래를 24시간 동안 할 수 있다는 이유로, 분기가 끝나기 전에는 세션을 더 진행할 수 있다. 
SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)의 투자 수익률을 통해 세 가지 자산 클래스의 투자 수익률을 비교하는 방식으로, 비트코인이 투자자들에게 가장 좋은 선택이 되었다는 것을 확인할 수 있다. 이번 연도 초에 투자한 1,000달러의 가치는 현재 1,673.84달러로, 이는 67.38%의 성과를 보여주고 있다. 
이번 년도 초에 각각의 1,000달러가 투자된 자산종목들은 현재 다음과 같은 가치를 보여주고 있다.
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th>자산</th>
<th>초기 투자</th>
<th>현재 가치</th>
<th>수익률</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPY</td>
<td>1,000달러</td>
<td>1,103.90달러</td>
<td>10.39%</td>
</tr>
<tr>
<td>금</td>
<td>1,000달러</td>
<td>1,080.40달러</td>
<td>8.04%</td>
</tr>
<tr>
<td>비트코인</td>
<td>1,000달러</td>
<td>1,673.84달러</td>
<td>67.38%</td>
</tr>
</tbody>
</table>
</figure>
미래의 방향 금융 시장의 주요 추진 기구로 분석가들은 향후 이번년도 안으로 이러한 랠리가 지속될 것으로 예상하고 있다. 그러나 미국의 소비자물가지수(CPI), 개인소비지출지수(PCE), GDP 성장, 논피닐 근로자 수, 10년 만기 미국 국채 수익률과 같은 경제 지표들은 투자자들에게 중요한 역할을 할 것으로 예상된다. 
블루칩 데일리 트렌드 리포트(Blue Chip Daily Trend Report)의 주요 기술 전문가인 래리 텐타렐리(Larry Tentarelli)는 Benzinga와의 만남에서 이러한 주요 지표들이 시장의 결과에 미칠 영향에 대해 강조했다. 그는 또한 미국 연방준비제도(Fed)의 행동이 시장에 미칠 가장 큰 영향으로 보고했다. 
앨리언츠 투자 관리(Allianz Investment Management)의 시니어 투자 전략가인 찰리 립리(Charlie Ripley)는 텐타렐리와 동의했다. 그는 시장에 미칠 가장 큰 영향은 연방준비제도(Fed)의 행동이라고 강조했다. &#8220;연방준비제도의 현재 입장은 올해 내 3차례의 금리 인하를 추구한다는 것이지만, 인플레이션 지표들이 점차 안정되어 있는 것 같다면 그들의 선은 금방 바뀔 수 있다&#8221;고 그는 말했다. 리플리는 이후에 집중리스크를 대비했다. 이번 년도에 연방준비제도와 어떠한 인플레이션 지표들 사이의 상관관계가 있을지에 대해 주목할 것으로 예상하고 있다. 
텐

Analyst Color

이번 분기에 비트코인, 골드 또는 S&P 500 중 어느 것이 당신을 더 부유하게 했나요? 이러한 자산 클래스에 투자된 $1000은 얼마의 수익을 가져왔을까요?

Comments

Humana

뉴스

에 대한 최신 뉴스 Humana (NYSE:HUM) 주식

월요일, 10월 21, 2024

일요일, 10월 06, 2024

수요일, 10월 02, 2024

일요일, 9월 15, 2024

화요일, 4월 02, 2024

금요일, 3월 29, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌